Lubiprostone Sucampo Pharmaceuticals Takeda Pharmaceutical

被引：0
|
作者：
Winpenny, JP [1 ]
机构：
[1] Univ E Anglia, Sch Med, Biomed Grp, Inst Hlth, Norwich NR4 7TJ, Norfolk, England
来源：
IDRUGS | 2005年 / 8卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Sucampo Pharmaceuticals Inc and Takeda Pharmaceutical Co Ltd are developing lubiprostone, a ClC-2 chloride channel activator and a bicyclic member of a series of fatty acid compounds, for the potential treatment of a number of gastrointestinal conditions, including constipation, irritable bowel syndrome, postoperative bowel dysfunction and opioid bowel dysfunction.
引用
收藏
页码：416 / 422
页数：7
相关论文
共 50 条
12345